Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arbutus Biopharma

3.31
+0.03100.95%
Volume:219.83K
Turnover:733.53K
Market Cap:634.15M
PE:-8.12
High:3.39
Open:3.27
Low:3.27
Close:3.28
Loading ...

Arbutus Biopharma Corp expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
28 Jul

Arbutus Biopharma Reacquires Rights to Imdusiran in China

MT Newswires Live
·
25 Jun

BRIEF-Arbutus Reacquires Greater China Rights to Imdusiran

Reuters
·
25 Jun

Arbutus Biopharma Corp. Announces New Scientific Advisory Board with Focus on Late-Stage Clinical Trials

Reuters
·
25 Jun

Arbutus Biopharma Holds Annual Shareholder Meeting

TIPRANKS
·
24 May

Arbutus Biopharma Corp. Conducted Annual Shareholder Meeting

Reuters
·
24 May

Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)

TIPRANKS
·
14 May

Arbutus Biopharma Q1 EPS $(0.13) Misses $(0.10) Estimate, Sales $1.76M Miss $1.78M Estimate

Benzinga
·
14 May

BRIEF-Arbutus Biopharma Q1 Revenue USD 1.8 Million Vs. IBES Estimate USD 1.78 Million

Reuters
·
14 May

Arbutus Biopharma Q1 2025: Revenue Up 20% to $1.8M, Net Loss Widens to $24.5M, EPS at $(0.13)

Reuters
·
14 May

GE HealthCare to feature latest advancements in diagnostic accuracy and patient-centered breast care at SBI 2025 Breast Cancer Imaging Symposium

Business Wire
·
25 Apr

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Zacks
·
24 Apr

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

GlobeNewswire
·
23 Apr

Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk

Dow Jones
·
07 Apr

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Zacks
·
01 Apr

Arbutus Biopharma Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Dow Jones
·
27 Mar

Arbutus Biopharma FY 2024 GAAP EPS $(0.38) Up From $(0.44) YoY, Sales $6.17M Down From $18.14M YoY

Benzinga
·
27 Mar

BRIEF-Arbutus Biopharma FY Revenue USD 6.2 Million Vs. IBES Estimate USD 6.18 Million

Reuters
·
27 Mar